Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | 15.13M | 16.81M | 17.05M | 17.87M | 17.84M |
| Gross Profit | -15.13M | -16.81M | -17.05M | -17.87M | -17.84M |
| SG&A Expenses | 8.50M | 9.91M | 9.67M | 9.60M | 10.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.26M | 20.35M | 20.36M | 21.43M | 21.86M |
| Operating Income | -17.26M | -20.35M | -20.36M | -21.43M | -21.86M |
| Income Before Tax | -17.84M | -20.31M | -19.87M | -21.32M | -21.54M |
| Income Tax Expenses | 757.40K | 617.40K | 536.80K | 46.60K | 57.10K |
| Earnings from Continuing Operations | -18.59 | -20.93 | -20.41 | -21.37 | -21.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.59M | -20.93M | -20.41M | -21.37M | -21.60M |
| EBIT | -17.26M | -20.35M | -20.36M | -21.43M | -21.86M |
| EBITDA | -17.22M | -20.31M | -20.32M | -21.39M | -21.82M |
| EPS Basic | -0.65 | -0.89 | -0.95 | -1.13 | -1.33 |
| Normalized Basic EPS | -0.39 | -0.54 | -0.58 | -0.71 | -0.83 |
| EPS Diluted | -0.65 | -0.89 | -0.95 | -1.13 | -1.33 |
| Normalized Diluted EPS | -0.39 | -0.54 | -0.58 | -0.71 | -0.83 |
| Average Basic Shares Outstanding | 113.26M | 102.14M | 91.43M | 78.75M | 64.92M |
| Average Diluted Shares Outstanding | 113.26M | 102.14M | 91.43M | 78.75M | 64.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |